Heavy menstrual bleeding, or menorrhagia, is excessive menstrual blood loss that disrupts the woman's physical, emotional, social or material quality of life. The modern definition deliberately moves away from a single millilitre cut-off because almost no woman measures her flow in millilitres in real life. Instead, a small set of practical markers is used and any one of them is enough to call a flow heavy: soaking through a regular pad or tampon every two hours or less, periods that last longer than seven days, passing clots larger than two and a half centimetres (about the size of an old 50-paisa coin), needing to double up pads or to layer a pad with a tampon, finding that the period interferes with sleep, work, school or social life, or the development of iron-deficiency anemia over time.

Two patterns help locate where in the body the problem is most likely to live. Heavy flow with regular timing each cycle points more often to a structural cause — fibroids, polyps, adenomyosis — because the hormonal cycle itself is still running on time but the uterus is bleeding more when it does shed. Heavy flow with irregular and unpredictable timing points more often to a hormonal or ovulatory cause — perimenopause, polycystic ovary syndrome, thyroid disorder, hyperprolactinemia — because the cycle itself has lost its rhythm.

The single most useful thing a woman can do before her gynec visit is to keep a pictorial bleeding chart for one or two cycles. A simple grid lets her tick whether each pad was lightly stained, half-soaked, fully soaked or overflowing, count any clots and note their size against a coin, and record the days the flow stopped her doing something. The chart turns a vague sense of heavy flow into an objective number the gynec can use to decide if the threshold for investigation has been crossed.

Heavy menstrual bleeding affects roughly one in four women across the reproductive lifespan, with prevalence rising through the 30s and peaking in the 40s as the cycle becomes anovulatory more often. In Indian community surveys it is consistently the commonest reason a woman of reproductive age presents to a gynec, well ahead of irregular periods or infertility, although it is also the symptom most often dismissed at home as just heavy periods.

The day-to-day cost of heavy bleeding is large and largely invisible from the outside. Many women plan their month around the period — avoiding travel, social events, weddings, festivals and exams during the heavy days — and lose two to four working or school days each month to a combination of flow, cramping and the fatigue of slowly worsening anemia. Adolescent girls miss school. Women in informal employment lose daily wages. White-coloured clothing, light upholstery and long meetings all become sources of anxiety about staining. The cumulative emotional load tracks closely with depression and anxiety scores in repeated surveys.

The medical cost is just as large. Iron-deficiency anemia develops quietly across many cycles, presenting as fatigue, breathlessness on stairs, palpitations, hair fall and difficulty concentrating long before anyone connects it to the period. Severe untreated bleeding can land a woman in the emergency department with haemoglobin in the single digits, needing intravenous iron or even a blood transfusion. The structural causes of heavy bleeding — polyps, fibroids, adenomyosis and rarely cancer — are picked up later than they need to be, which both increases the eventual treatment burden and reduces the chance of a uterus-sparing solution.

Modern gynecology classifies the causes of heavy menstrual bleeding using the FIGO PALM-COEIN system, which usefully splits the long list into two halves — structural causes that can be seen on imaging (PALM) and non-structural causes that cannot (COEIN). This matters because the right treatment depends entirely on the cause, and the same flow can come from very different problems that need very different answers.

The PALM (structural) half covers four conditions. Polyps are small soft outgrowths from the lining of the uterus or the cervix that bleed easily and tend to cause both heavy bleeding and spotting between periods; they are typically removed at a quick hysteroscopy. Adenomyosis is the invasion of uterine lining tissue into the muscular wall of the uterus, classically causing very painful and very heavy periods in the 30s and 40s; see adenomyosis vs endometriosis in India. Leiomyoma, more commonly called fibroid, is a benign smooth-muscle tumour of the uterus that is extremely common in Indian women and causes heavy bleeding especially when it sits just under the lining (submucosal); see uterine fibroids in India. Malignancy and pre-malignant endometrial hyperplasia are uncommon but vital to rule out, particularly in women over 40 and in any woman with risk factors such as obesity, diabetes, PCOS or unopposed estrogen.

The COEIN (non-structural) half covers five further groups. Coagulation disorders, especially undiagnosed von Willebrand disease, are surprisingly common (roughly 1 in 10 of teenagers with very heavy periods from menarche have an underlying bleeding disorder). Ovulatory dysfunction covers PCOS, perimenopause and the anovulatory cycles common in the first one or two years after menarche, all of which leave the uterine lining over-stimulated by unopposed estrogen and prone to heavy unpredictable bleeds; see what irregular periods can mean. Endometrial causes refer to local disorders of haemostasis within an otherwise normal-looking lining. Iatrogenic causes include medications, particularly anticoagulants such as warfarin and the newer oral anticoagulants, copper IUDs, and some hormonal regimens. Not-otherwise-classified is the small residual bucket for cases that defy these categories.

The diagnostic pathway in India is built up in clear steps so that the simpler tests come first and the more invasive ones are reserved for when they are needed. The first step is the history, which is more useful than any single test. The gynec will ask about cycle length, day-by-day flow, the size and number of clots, the impact on sleep, work and social life, the age at menarche, any prior pregnancies, any bleeding from gums or nose or with dental work (a clue to a coagulation problem), current medications including anticoagulants and IUDs, and family history of fibroids or bleeding disorders.

A pelvic examination then assesses uterine size and tenderness, looks for any cervical lesion that might bleed on contact, and identifies a palpable mass suggesting a fibroid. A urine pregnancy test is added in any sexually active woman to rule out pregnancy-related bleeding, which is managed very differently.

First-line laboratory tests are simple, low-cost and high-yield. A complete blood count (CBC, 300 to 600 rupees) reveals the haemoglobin and the size and colour of the red cells; iron-deficiency anemia from chronic heavy bleeding shows up as microcytic hypochromic anemia. Serum ferritin (400 to 1,000 rupees) shows the actual iron stores, which fall before the haemoglobin does. A thyroid stimulating hormone (TSH, 200 to 500 rupees) test catches under-active or over-active thyroid as a treatable cause. A coagulation profile (PT, aPTT, optionally von Willebrand factor) costs roughly 1,000 to 3,000 rupees and is added in any woman who has had very heavy periods from menarche, frequent nose bleeds or easy bruising, or a family history of bleeding disorder.

Imaging then maps the uterus and ovaries. A transvaginal ultrasound (TVS) costs 500 to 2,500 rupees in India and is the preferred first scan because it gives a much clearer image of the lining and the wall of the uterus than a transabdominal scan. It identifies fibroids and their location (submucosal, intramural, subserosal), endometrial polyps, the bulky symmetrical uterus of adenomyosis, ovarian cysts and an unusually thick endometrium that needs further evaluation.

Second-line investigations come in when the picture is still unclear or when an intrauterine cause is suspected. A hysteroscopy (15,000 to 50,000 rupees in a private hospital, often free at Ayushman Bharat empanelled facilities) passes a thin camera into the uterine cavity and lets the gynec actually see polyps, submucosal fibroids and an irregular lining; small lesions can be both diagnosed and removed in the same sitting. An endometrial biopsy (2,000 to 8,000 rupees) samples the lining and is added for any woman over 40, for women under 40 with persistent unexplained heavy bleeding, and for any woman with risk factors for endometrial cancer or hyperplasia.

For most women who simply want to bleed less without adding hormones, tranexamic acid is the right first medicine and is widely available in India under brand names such as Pause, Trapic MF and several generics. It is an antifibrinolytic, which means it slows the breakdown of the small blood clots that the uterus normally uses to seal off bleeding lining vessels during a period. The clinical effect is a 30 to 50 percent reduction in measured flow across a treated cycle, often noticed by the woman within one or two cycles.

The typical regimen is one gram (two 500 mg tablets) taken three to four times a day, started on the first day of heavy flow and continued only for the four or five days that the flow is actually heavy. The tablets are not taken throughout the cycle and not on light or absent days. A strip of ten 500 mg tablets costs roughly 100 to 300 rupees, so a full heavy-day course works out to less than the cost of a single month of pads for most women.

Tranexamic acid is reassuring on safety in this setting. It does not affect fertility, does not delay or shift the period, and does not change ovulation. The short course taken only during menstrual days does not raise the risk of clots in women without a personal history of deep vein thrombosis or known thrombophilia. It can be taken alongside iron tablets and is often paired with them when anemia is present. The commonest side effects are mild nausea and occasional diarrhoea, both usually settling after the first cycle. Women on combined oral contraceptive pills, those with a personal history of clots, recent surgery or active eye problems should discuss it with their gynec before starting.

Mefenamic acid (500 mg three times a day during heavy days) is a useful non-hormonal alternative or add-on that also reduces flow modestly and treats menstrual cramps in the same dose. A strip costs roughly 50 to 200 rupees. Together with tranexamic acid it forms the standard non-hormonal first-line package for menorrhagia in India.

When a woman also wants contraception, has acne or hirsutism alongside heavy bleeding (suggesting a PCOS overlap), or has not responded fully to tranexamic acid, the hormonal options become the right next step. They work by either thinning the endometrium so there is less to shed each month, by overriding the natural cycle with a stable hormonal pattern, or both, and they typically deliver a 30 to 50 percent reduction in flow with the added benefit of more predictable timing.

Combined oral contraceptive pills (Yasmin, Diane-35, Krimson 35, Femilon and several generics) are the most commonly prescribed hormonal first-line option, costing roughly 100 to 500 rupees a month depending on brand. They contain both estrogen and progestin, are taken daily for 21 days followed by a 7-day pill-free week (or with 7 placebo tablets in 28-day packs), and produce a predictable, lighter and less painful withdrawal bleed during the pill-free week. They also provide reliable contraception and treat hormonal acne and hirsutism. They are not suitable for women with a personal history of clots, smokers over 35, women with uncontrolled high blood pressure, and women with migraine with aura.

Progestin-only options suit women who cannot take estrogen. The progestin-only mini pill is taken daily without a break and is particularly useful in breastfeeding women and women over 35 who smoke. Cyclical oral progestin, typically norethisterone 5 mg twice a day from day 5 to day 26 of the cycle, is an older but still widely used regimen that thins the lining and produces a controlled withdrawal bleed during the seven-day off-week; it is useful when the cycle is anovulatory and unpredictable and is one of the cheapest options at roughly 50 to 200 rupees a cycle.

Two practical points help. First, expect breakthrough spotting in the first three months of any new hormonal option as the lining adjusts to the new hormonal pattern; this is not a treatment failure and almost always settles by the fourth or fifth month. Second, review the response at three months — if the flow has dropped meaningfully and the side effects are tolerable, continue; if not, the gynec can either switch to a different formulation or step up to the LNG-IUS or surgical options below.

The levonorgestrel-releasing intrauterine system (LNG-IUS), sold in India as Mirena and Skyla, is the single most effective medical treatment for heavy menstrual bleeding and is correctly described in guidelines worldwide as the gold standard. It is a small T-shaped device, slightly larger than a paperclip, that is inserted into the uterus during a brief outpatient procedure and slowly releases a small amount of the progestin levonorgestrel directly onto the uterine lining over five years.

The clinical effect is dramatic. Across studies, flow falls by 80 to 95 percent within six to twelve months of insertion, and a meaningful proportion of women — roughly 20 to 50 percent depending on the study and the duration of use — stop having periods altogether (amenorrhea) without any harm. Cramping reduces in parallel, and the device also provides reliable contraception of similar efficacy to female sterilisation, with the major advantage of being fully reversible the moment it is removed.

In India the device itself costs roughly 15,000 to 25,000 rupees, with an insertion fee of an additional 5,000 to 15,000 rupees in private hospitals, and is significantly subsidised or free in government and teaching hospitals. Ayushman Bharat (PM-JAY) covers the device and insertion for eligible families at empanelled facilities. Spread across five years of use, the daily cost works out to less than the cost of two pads, which makes it one of the most cost-effective treatments in gynecology.

Two expectations help. First, breakthrough spotting and irregular light bleeding are common in the first three to six months as the lining adjusts, after which most women settle into very light periods or no periods at all; the temptation to remove the device during this settling phase is the main reason women miss out on the longer-term benefit. Second, the LNG-IUS does not cause infertility — fertility returns to baseline within one to three cycles of removal — and there is no upper age limit on its use up to menopause. Common myths about Mirena are addressed in the myths section below.

Surgery becomes the right answer when medical treatment has been tried adequately and has not controlled the bleeding, when a structural cause needs physical removal, when the woman has completed her family and wants a one-time definitive solution, or when there is suspicion of malignancy. The surgical ladder runs from the smallest, most uterus-sparing procedure to the most definitive, and the right rung depends on the cause, the age, the family-completion status and the woman's own preferences.

Hysteroscopic polypectomy is the lowest rung and removes an endometrial polyp through a thin camera passed up through the cervix, with no skin incision. It costs roughly 15,000 to 50,000 rupees in private hospitals, is often a day-care procedure, and is covered free for eligible families at Ayushman Bharat empanelled centres. The polyp tissue is sent for histology to confirm it is benign.

Myomectomy removes fibroids while preserving the uterus and is the right operation for a woman who wants to retain fertility or simply wants to keep her uterus. The route — open abdominal, laparoscopic or hysteroscopic — depends on the size and location of the fibroids and the surgeon's expertise. Costs range from roughly 30,000 to 2,50,000 rupees depending on route and institution, with Ayushman Bharat coverage available at empanelled facilities.

Endometrial ablation destroys the uterine lining using heat, cold or radiofrequency in a brief procedure that costs roughly 50,000 to 1,50,000 rupees. It dramatically reduces bleeding without removing the uterus, but it is reserved for women whose family is complete because subsequent pregnancy is unsafe; it is most often offered in the mid-40s when the LNG-IUS has been tried and has not suited.

Uterine artery embolisation is a minimally invasive radiology procedure that blocks the blood supply to large fibroids, shrinking them and reducing bleeding, at a cost of roughly 1,50,000 to 3,00,000 rupees. It preserves the uterus, avoids a major operation and is a good option for selected women who are not surgical candidates.

Hysterectomy, the surgical removal of the uterus, is the definitive treatment and ends menstrual bleeding completely. It is reserved for women who have completed their family, in whom medical options and uterus-sparing surgery have either failed or are not appropriate, or in whom malignancy is confirmed. Costs range from roughly 50,000 to 3,00,000 rupees depending on route (vaginal, laparoscopic, abdominal) and institution, with full Ayushman Bharat coverage at empanelled facilities. Modern Indian practice strongly favours uterus-sparing options first and uses hysterectomy only when the medical and uterus-preserving ladder has been exhausted.

Iron-deficiency anemia rides alongside heavy menstrual bleeding so consistently that the two should always be diagnosed and treated together rather than in sequence. Treating only the bleeding while ignoring a haemoglobin of nine leaves the woman exhausted for months while the cause is being worked up; treating only the anemia while the bleeding continues simply pours iron into a leaking bucket.

The parallel work-up is straightforward. A CBC and serum ferritin are done at the same visit as the cycle history, and if the haemoglobin is below 12 or the ferritin is below 30, oral iron treatment is started immediately at the same visit as the bleeding work-up. Indian government services provide iron and folic acid (IFA) tablets free of charge under the Anemia Mukt Bharat programme through anganwadis, schools, primary health centres and ASHA workers, alongside iron-rich diet counselling. A typical course is one tablet daily for three to six months, with haemoglobin and ferritin rechecked at three months. For related reading see anemia in pregnancy in India.

When the haemoglobin is severely low (typically under 8) or the woman cannot tolerate oral iron or is not absorbing it, intravenous iron sucrose or ferric carboxymaltose is used in a brief outpatient infusion, costing roughly 2,000 to 5,000 rupees a dose. Two to three doses given over two to four weeks typically restore the haemoglobin and replenish stores faster than several months of oral iron. In the rare situation of severe symptomatic anemia (haemoglobin under 7 with breathlessness, palpitations or chest pain) a blood transfusion is given, which is free of cost at government and Red Cross blood banks.

Diet matters as a long-term support though it cannot substitute for iron tablets in the active treatment of established anemia. An Indian iron-rich plate combines green leafy vegetables (palak, methi, drumstick leaves), millets (ragi, bajra), jaggery, dates, eggs, chicken and red meat where the diet allows, and pulses with rice or roti to improve absorption. Vitamin C foods with meals (amla, lemon, guava, citrus, tomato) significantly improve non-haem iron absorption. Tea and coffee block iron absorption sharply, so leave a one-hour gap on either side of the iron tablet and around iron-rich meals.

Heavy menstrual bleeding is one of the gynec conditions where India offers a genuinely tiered care pathway, and choosing the right tier for the right stage saves both money and time. The Community Health Centre (CHC) and Primary Health Centre (PHC) are the entry point for free haemoglobin testing, free IFA tablets under Anemia Mukt Bharat, the first round of tranexamic acid and a referral upward when imaging or surgery is needed. The Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA) provides a free gynec examination on the 9th of every month at participating government facilities, which is a particularly low-friction first contact for women who have never seen a gynec before.

District government hospitals and the major teaching hospitals (AIIMS in multiple cities, KEM in Mumbai, CMC Vellore, JIPMER in Puducherry, and the state medical colleges) provide the full diagnostic work-up including transvaginal ultrasound, hysteroscopy and endometrial biopsy, and offer the full range of medical and surgical treatment at very low or zero cost. They are particularly strong for complex surgery, for any case with a malignancy concern, and for the cost-sensitive end of the LNG-IUS pathway because the device and insertion are often free under government schemes and PMJAY.

Private hospital chains (Apollo, Fortis, Manipal, Max, Cloudnine, Motherhood and the larger standalone women's hospitals) typically offer faster appointment slots, round-the-clock operation theatres, day-care hysteroscopy and a single point of contact for the full pathway. Pricing is higher and depends heavily on city, hospital tier and surgeon — a hysteroscopic polypectomy at a metro corporate hospital can cost three to five times what it costs at a teaching hospital — and most Indian women combine the two systems, using the private system for the first consultation and ultrasound and the government system for surgery and free IFA support.

Two India-specific schemes broaden access. Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY) provides cashless coverage up to 5 lakh rupees per family per year at empanelled hospitals for eligible families, covering the LNG-IUS, hysteroscopy, myomectomy, ablation, embolisation and hysterectomy in full. State-specific schemes (Chief Minister's Comprehensive Health Insurance in Tamil Nadu, Mahatma Jyotirao Phule Jan Arogya Yojana in Maharashtra, Aarogyasri in Andhra Pradesh and Telangana, and others) layer additional coverage on top. Carry the Ayushman card, Aadhaar and ration card to the first appointment to streamline eligibility.

• Soaking through a pad or tampon every 30 minutes or less for two consecutive hours — this is haemorrhage-level flow and needs same-day assessment at the emergency department for stabilisation, intravenous fluids and a haemoglobin check.
• Dizziness, fainting, light-headedness on standing, palpitations or chest pain alongside heavy bleeding — these point to acute volume loss or severe anemia and need emergency review the same day.
• Passing clots larger than a golf ball, or passing many clots in quick succession — same-day gynec assessment, particularly if accompanied by severe pain.
• Heavy bleeding with high fever (over 38 degrees Celsius), foul-smelling discharge or severe pelvic pain — assume infection (endometritis, pelvic inflammatory disease) until proven otherwise and seek same-day care.
• Any vaginal bleeding more than 12 months after the final period (post-menopausal bleeding), however light — always a same-week gynec appointment for transvaginal ultrasound and biopsy because endometrial cancer needs to be ruled out.
• Sudden very heavy bleeding in a woman on anticoagulant medication (warfarin, dabigatran, apixaban, rivaroxaban) or in a woman with a known coagulation disorder — same-day medical review because the medication can amplify the bleed and reversal may be needed.
• Heavy bleeding in a woman who is or could be pregnant — go to the emergency department the same day to rule out miscarriage, ectopic pregnancy and other pregnancy-related bleeding which is managed very differently.

• Myth: heavy periods are just how some women are made and need to be put up with. Fact: heavy menstrual bleeding is a defined medical condition with a well-mapped diagnostic pathway and at least six effective treatment options ranging from a single tablet during heavy days to definitive surgery; almost no woman needs to live with it.
• Myth: an iron tablet is enough — if I take iron I will be fine. Fact: iron treats the consequence (anemia) but does nothing about the cause; without addressing the bleeding the iron is being poured into a leaking bucket and the symptoms will return as soon as iron is stopped.
• Myth: hysterectomy is the only real solution for heavy periods. Fact: hysterectomy is the last rung of the ladder and is reserved for women in whom medical and uterus-sparing surgical options have been exhausted; the LNG-IUS, hormonal pills, tranexamic acid, polypectomy, myomectomy, ablation and embolisation all sit below it and resolve the problem for the majority of women.
• Myth: the Mirena LNG-IUS will make me infertile or cause cancer. Fact: Mirena is fully reversible — fertility returns within one to three cycles of removal — and is actually protective against endometrial cancer because it keeps the lining thin; it has the strongest safety record of any intrauterine device.
• Myth: tranexamic acid causes clots, so it is dangerous to take during periods. Fact: in the short three to five-day menstrual courses used for heavy bleeding, tranexamic acid does not raise clot risk in women without a personal history of deep vein thrombosis or known thrombophilia; it is recommended worldwide as a first-line non-hormonal treatment for menorrhagia.